eISSN: 1896-9151
ISSN: 1734-1922
Archives of Medical Science
Current issue Archive Manuscripts accepted About the journal Special issues Editorial board Abstracting and indexing Subscription Contact Instructions for authors Ethical standards and procedures
SCImago Journal & Country Rank
1/2020
vol. 16
 
Share:
Share:
more
 
 
abstract:
Public health

Hepatitis B virus screening in patients with non-Hodgkin lymphoma in clinical practice in Poland – a report of the Polish Lymphoma Research Group

Ewa Kalinka
1
,
Joanna Drozd-Sokołowska
2
,
Anna Waszczuk-Gajda
2
,
Joanna Barankiewicz
3
,
Elżbieta Zalewska
4
,
Igor Symonowicz
1
,
Ewa Lech-Marańda
3

1.
Department of Oncology, Polish Mother’s Memorial Hospital – Research Institute, Lodz, Poland
2.
Department of Hematology, Oncology and Internal Diseases, Warsaw Medical University, Warsaw, Poland
3.
Department of Hematology, Institute of Hematology and Transfusion Medicine, Warsaw, Poland
4.
Statistical Methods Unit, University of Lodz, Lodz, Poland
Arch Med Sci 2020; 16 (1): 157–161
Online publish date: 2019/07/18
View full text
Get citation
ENW
EndNote
BIB
JabRef, Mendeley
RIS
Papers, Reference Manager, RefWorks, Zotero
AMA
APA
Chicago
Harvard
MLA
Vancouver
 
Introduction
The risk of HBV reactivation is important in lymphoma patients receiving immunosuppressive chemotherapy containing steroids or anti-CD20 antibodies. We aimed to establish the prevalence of HBV Ag and anti-HBc serologic positive results in patients with non-Hodgkin lymphoma (NHL) and chronic lymphocytic leukemia (CLL) in Poland before anti-CD20 therapy initiation; to assess the frequency of insufficient HBV screening; and to assess the association between inadequate HBV screening and diagnosis according to the WHO classification and age or gender.

Material and methods
We retrospectively collected data from 805 patients with non-Hodgkin lymphoma and chronic lymphocytic leukemia treated in 2016–2018.

Results
We found a positive result of HBsAg in 13 (1.16%), and a negative result in 633 (78.64%) patients. The test was not done in 159 (19.75%) patients. In the HBsAg negative subgroup of 633 patients, we found that the anti-HBc was positive in 52 (8.22%), negative in 303 (47.87%) and not done in 278 patients. In 136 out of 805 (16.9%) patients diagnostics tests were not performed before therapy initiation. We found that age is significantly associated (p = 0.0002) with the lack of HBV infection screening, and in CLL this risk is significantly (p = 0.024) higher (by 49%) compared with other WHO diagnosis subgroups.

Conclusions
In Polish lymphoma patients the incidence of positive HBsAg and/or anti-HBc results is consistent with the prevalence in the United States or Australia. The adherence to appropriate HBV screening guidelines in Polish centers is not sufficient. We should intensify educational strategies in the global oncohematologic medical community.

keywords:

screening, chronic lymphocytic leukemia, hepatitis B virus, non-Hodgkin lymphoma, anti-CD20 treatment

Quick links
© 2020 Termedia Sp. z o.o. All rights reserved.
Developed by Bentus.
PayU - płatności internetowe